Physician

James Marcellus Barry, M.D.

According to 2025 Medicare claims, James Barry, M.D. (NPI: 1952304743) practices neurology in the Fort Worth-Arlington-Grapevine, TX market, with the plurality of this provider's patient population coming from Tarrant, TX. This provider's primary affiliated billing organization is MID CITIES NEUROLOGY ASSOCIATES, P.A. (NPI: 1023119336; TIN: 752600199) and primary practice location at 76021-6606. Barry is affiliated with the UT Southwestern Accountable Care Network (ACO ID: D0211), participating under the REACH model.

Barry's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 920 traditional Medicare patients, billed 97,924 HCPCS/CPT codes, and received $2,730,965 in Medicare payments. The top billing code was 99204 (New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more). Part D data shows 3,829 prescription claims across 670 beneficiaries totaling $1,270,233 in drug costs, led by Gamunex-C (Immune Globul G/Gly/Iga Avg 46). DME data shows 30 claims. Open Payments data shows 279 records totaling $8,565. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $1,663,635 to $2,730,965. Concurrently, Part D prescription costs have changed little. In contrast, DME billing represents a smaller volume and moved sharply higher in recent years, from $855 to $0.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	633	115,696	$1,663,635
2016	543	77,020	$1,100,907
2017	641	59,876	$788,737
2018	656	59,705	$588,360
2019	614	28,639	$555,097
2020	595	17,822	$341,855
2021	614	29,404	$662,848
2022	774	81,903	$2,223,899
2023	1,092	131,545	$4,393,860
2024	920	97,924	$2,730,965

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	323	1,971	$1,078,962
2016	319	1,719	$1,086,469
2017	363	1,988	$1,121,553
2018	364	1,970	$926,473
2019	455	2,464	$1,549,865
2020	394	2,459	$1,388,935
2021	446	2,627	$1,020,043
2022	498	2,885	$1,239,518
2023	582	3,476	$1,138,361
2024	670	3,829	$1,270,233

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	30	$84,847

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99204	New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more	141	141	$117
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	485	665	$81
J0897	Injection, denosumab, 1 mg	191	12,750	$20
96372	Injection of drug or substance under skin or into muscle	227	337	$11
96127	Assessment of emotional or behavioral problems	169	185	$4

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Gamunex-C	Immune Globul G/Gly/Iga Avg 46	52	1,267	$511,429
Nuplazid	Pimavanserin Tartrate	33	990	$172,710
Nuedexta	Dextromethorphan Hbr/Quinidine	12	780	$37,310
Emgality Pen	Galcanezumab-Gnlm	32	1,230	$29,214
Dalfampridine Er	Dalfampridine	49	2,070	$27,155

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J1561	Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg	N	N/R	13	$77,265
Q2052	Services, supplies and accessories used in the home for the administration of intravenous immune globulin (ivig)	N	N/R	17	$7,582

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	278	$4,693	ABBVIE INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	1	$3,872	Genentech, Inc.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for James Marcellus Barry, M.D.?

Tedicare shows public-source Medicare data for James Marcellus Barry, M.D. (NPI 1952304743), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does James Marcellus Barry, M.D. have ACO affiliation data?

James Marcellus Barry, M.D. is shown with ACO affiliation data for UT Southwestern Accountable Care Network (REACH, ACO ID D0211).

What billing organization is linked to James Marcellus Barry, M.D.?

James Marcellus Barry, M.D. is linked to MID CITIES NEUROLOGY ASSOCIATES, P.A. (billing NPI 1023119336) in the available physician profile data.

Does James Marcellus Barry, M.D. have Open Payments data?

James Marcellus Barry, M.D. has 279 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.